A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients

Exclusion Criteria

• •Co-existing Condition:
• •Patients with the following condition are excluded:
• •Unable or unwilling to comply with study procedures.
• •Concurrent Medication:
• •Excluded:
• •Chemoprophylactic therapy for mycobacterial infection.
• •Any nonstudy prescription medications without approval of investigator.
• •Patients with the following prior conditions are excluded:
• •History of grade 3 or 4 toxicity to \<= 600 mg/day AZT.
• •History of intolerance to lactose.
• •Chronic diarrhea within 6 months prior to study entry.
• •Unexplained intermittent or chronic fever, defined as temperature \>= 38.5 C for any 7 days within the 30 days prior to study entry.
• •Prior Medication:
• •Excluded:
• •Antiretroviral therapy within 2 weeks prior to study entry.
• •Prior HIV vaccines.
• •Biological response modifiers within 30 days prior to study entry.
• •Prior foscarnet.
• •Any investigational drug with a washout \< 5 half-lives prior to study entry.
• •Any medications known to alter renal, hepatic, or hematologic / immunologic function (such as barbiturates, phenothiazines, cimetidine, immunomodulators, etc.) within 14 days prior to study entry.
• •Recent history of alcohol and/or drug abuse.